Glad tidings on the health-care front, as Melbourne, Australia came out with news Monday.
Propanc Biopharma Inc (OTC:PPCB) announced today that the mode of action of the company’s lead product candidate, PRP, a formulation consisting of two proenzymes, has been clarified by the company’s researchers. The method is achieved by suppressing pathways relating to the Epithelial to Mesenchymal Transition (EMT) and metastasis.
The company says the EMT is a biological process by which cells become motile and invasive, but in cancer stem cells, results in metastasis, a process whereby secondary tumors are formed often in remote distances from a primary tumor, causing the cancer to return and spread.
And the scientific community is catching on. Data relating to these key findings were published in Scientific Reports, an online open access journal from the Publishers of Nature, entitled, “Pancreatic Proenzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumor engrafting.”
Shares in PPCB gained nearly seven cents, or 8.4%, to 89.95 cents early Monday afternoon, on volume of more than 18,000 shares
